Zenas Biopharma Inc [NASDAQ: ZBIO] traded at a high on 2025-11-26, posting a 1.68 gain after which it closed the day’ session at $40.53.
The results of the trading session contributed to over 230346 shares changing hands. Over the past one week, the price volatility of Zenas Biopharma Inc stands at 8.45% while the volatility over the past one month is 8.28%.
The market cap for ZBIO stock reached $2.18 billion, with 42.21 million shares outstanding and 13.21 million shares in the current float. Compared to the average trading volume of 409.18K shares, ZBIO reached a trading volume of 230346 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Zenas Biopharma Inc [ZBIO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZBIO shares is $45.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZBIO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wedbush have made an estimate for Zenas Biopharma Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 20, 2025. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on February 04, 2025, representing the official price target for Zenas Biopharma Inc stock. Previously, the target price had yet another raise to $30, while H.C. Wainwright analysts kept a Buy rating on ZBIO stock.
The Price to Book ratio for the last quarter was 8.71, with the Price to Cash per share for the same quarter was set at 5.42.
How has ZBIO stock performed recently?
Zenas Biopharma Inc [ZBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.10. With this latest performance, ZBIO shares gained by 34.25% in over the last four-week period, additionally plugging by 305.30% over the last 6 months – not to mention a rise of 394.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZBIO stock in for the last two-week period is set at 71.19, with the RSI for the last a single of trading hit 2.86, and the three-weeks RSI is set at 2.73 for Zenas Biopharma Inc [ZBIO]. The present Moving Average for the last 50 days of trading for this stock 28.03, while it was recorded at 37.86 for the last single week of trading, and 15.60 for the last 200 days.
Zenas Biopharma Inc [ZBIO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Zenas Biopharma Inc [ZBIO] shares currently have an operating margin of -1304.64% and a Gross Margin at 99.47%. Zenas Biopharma Inc’s Net Margin is presently recorded at -1265.99%.
Zenas Biopharma Inc (ZBIO) Capital Structure & Debt Analysis
According to recent financial data for Zenas Biopharma Inc. ( ZBIO), the Return on Equity (ROE) stands at -68.33%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -52.35%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Zenas Biopharma Inc’s Return on Invested Capital (ROIC) is -96.59%, showcasing its effectiveness in deploying capital for earnings.
Zenas Biopharma Inc (ZBIO) Efficiency & Liquidity Metrics
Based on Zenas Biopharma Inc’s (ZBIO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Zenas Biopharma Inc (ZBIO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Zenas Biopharma Inc. (ZBIO) effectively leverages its workforce, generating an average of -$1460769.23 per employee. The company’s liquidity position is robust, with a Current Ratio of 5.66% and a Quick Ratio of 5.66%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Zenas Biopharma Inc [ZBIO]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Zenas Biopharma Inc go to 32.18%.
Insider trade positions for Zenas Biopharma Inc [ZBIO]
There are presently around $63.59%, or 86.18%% of ZBIO stock, in the hands of institutional investors.
